Lets drug makers get special status for older drugs to encourage new uses for common diseases, potentially helping patients.
Patients might see new uses for older drugs that treat common conditions. This bill would create a new category called "priority research drugs." It would change how rebates are calculated for these older drugs under Medicare and Medicaid. This aims to encourage drug companies to find new uses for existing medications.
Today, new uses for older drugs might be treated as "line extensions," affecting how much drug companies pay in rebates to Medicare and Medicaid. This can make it less appealing for companies to research new uses for these drugs. If this bill passes, a new "priority research drug" designation would be created. Drugs with this status would not be treated as "line extensions" for rebate calculations, aiming to encourage companies to develop new treatments for common conditions using older medications.
HR 2542 · 119th Congress · April 1, 2025 · AI Summary by gemini-2.5-flash · 8/10
Sign in to see your representatives' phone numbers
2 filings mentioned this bill
Amounts reflect total quarterly lobbying spend reported to the Senate, not bill-specific spending. Source: Senate LDA filings.